Cortexyme announces clinical hold on atuzaginstat's investigational new drug application

South san francisco, calif.--(business wire)---- $crtx--cortexyme, inc. (nasdaq: crtx), a clinical-stage biopharmaceutical company focused on alzheimer's and other degenerative diseases, today announced that the company received a letter from the u.s. food and drug administration (fda) on january 25, 2022 placing a full clinical hold on atuzaginstat's (cor388) investigational new drug application (ind 134303). the company plans to provide additional updates pending continued engagement with fda. cortexym
QNCX Ratings Summary
QNCX Quant Ranking